Status:
COMPLETED
Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.
Conditions:
Glabellar Lines
Eligibility:
All Genders
19-65 years
Phase:
PHASE1
Brief Summary
To evaluate the safety of 12-week administration of DWP712 inj. in subjects with moderate to severe glabellar lines.
Eligibility Criteria
Inclusion
- Subjects with facial wrinkle scale (FWS) score of visual appearance of glabellar lines ≥2 (moderate) at maximum frown as assessed by the investigator at screening
Exclusion
- \-
Key Trial Info
Start Date :
November 28 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 21 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06212960
Start Date
November 28 2023
End Date
March 21 2024
Last Update
April 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chung-Ang University Hosptial
Seoul, South Korea